Stemline Therapeutics Inc (STML) Received its Third Buy in a Row


After Piper Jaffray and Cowen & Co. gave Stemline Therapeutics Inc (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $35. The company’s shares closed on Friday at $13.62.

Selvaraju commented:

“As we roll forward the DCF analysis, the estimated market value of the firm has increased to $1.5B from $1.46B, which includes the asset value for 15% discount rate and 2% terminal growth rate. The company has approximately 43.6M shares outstanding. Probabilities of success ascribed to SL-401 and SL-701 are 100% and 45%, respectively.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.6% and a 38.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $30.33, a 122.7% upside from current levels. In a report issued on March 11, Piper Jaffray also maintained a Buy rating on the stock with a $23 price target.

See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.04 million. In comparison, last year the company had a GAAP net loss of $21.75 million.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts